A Cold Chain Process Validation Guide: Part 4: Component Qualification / Installment Qualification (CQ/IQ)
Robust test standards and test methods must be in place in your quality management...
read DetailsIn today’s biopharmaceutical landscape, developing drugs for rare diseases presents unique challenges. The FDA’s recent guidance on “Rare Diseases: Considerations for the Development of Drugs and Biological Products” sheds light on critical considerations in the drug development process. While not signaling a paradigm shift in regulatory expectations, this guidance significantly impacts biologic drug product manufacturing and cold chain logistics.
Navigating these challenges is crucial, especially considering the limited medical and scientific knowledge, poorly understood natural history data, sample size constraints, and lack of drug development experience associated with rare diseases.
One of the most significant implications of this guidance lies in the process validation for distribution channels. Maintaining drug quality throughout the supply chain, particularly with the FDA’s focus on cold chain logistics for rare disease drugs, requires stricter controls to ensure stability and efficacy.
At Modality Solutions, we understand the complexities of biopharma cold chain engineering. Our expertise goes beyond standard practices, offering solutions in transport simulation and regulatory filing to address the evolving needs of the industry.
Robust test standards and test methods must be in place in your quality management...
read DetailsDeveloping mature quality systems is one of the biggest challenges and one of the...
read DetailsAre you aware of the open data files published online by the FDA? This...
read Details